Neonatal Abstinence Syndrome:
|
|
- Allen Moore
- 6 years ago
- Views:
Transcription
1 Neonatal Abstinence Syndrome: Rethinking Our Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital
2 Patrick, et al. Journal of Perinatology. 2015; 35: Source:
3 Patrick, et al Journal of Perinatology, 2015
4
5 Source: Grossman Family Album
6
7
8 Source: Langenfeld, et al. Drug and Alcohol Dependence 2005;77:31 6.
9 Source: Jackson L, et al. Archives of Disease in Childhood 2004;89: F300 4.
10 Source: Coyle MG. Journal of Pediatrics 2002;140:561 4
11 Source: MS Brown et al. Journal of Perinatology 2014; (1-6)
12 Agthe, et al. Pediatrics 2009;123:e Source:
13 Standard Approach Medications NICU Finnegan Scores Medication Dosing Staff cares for the baby
14 Length of Stay: Methadone-Exposed Infants LOS (days) P < June 2006 July
15 Medication Studies DTO vs. DTO plus clonidine: 17 days vs. 12 days Morphine vs. Phenobarbitone: 8 days vs. 12 days Morphine vs. DTO 30 days vs. 27 days DTO vs. DTO plus Phenobarbitone 79 days vs. 38days Methadone vs. Morphine 17 days vs. 24 days
16
17
18
19 Percent of NAS Patients Treated with Morphine 100.0% 90.0% 80.0% % Treated with Morphine 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Year
20 Length of Stay: Methadone exposed infants Mean=22.5 UCL 47.1 LENGTH OF STAY (Days) LCL 0.0 ADMIT DATE
21 Asti, et al., Pediatrics 2015;135
22 The standard approach: why? Medications
23 Source: Grossman Family Album Abraham, et al. J Obstet Gynaecol Can 2010;32(9):
24 Intervention 1 Focus on non-pharmacologic care 24
25 Length of Stay: Methadone exposed infants 70.0 Standardized non-pharm care UCL Mean=22.5 LENGTH OF STAY (Days) Mean= LCL 0.0 ADMIT DATE
26 The standard approach: why? Medications NICU
27 Source:
28
29 Source:
30 Intervention 2 Direct transfer to the general inpatient unit 30
31 Length of Stay: Methadone exposed infants Standardized non-pharm care Direct transfer to inpatient unit 50.0 UCL Mean=22.5 LENGTH OF STAY (Days) CL Mean=13.2 Mean= LCL 0.0 1/30/08 6/12/08 7/18/08 10/15/08 12/1/08 1/13/09 2/7/09 4/6/09 5/13/09 6/14/09 9/10/09 10/5/09 12/18/09 2/23/10 3/19/10 6/23/10 9/23/10 11/23/10 12/18/10 2/17/11 3/8/11 4/27/11 5/19/11 7/26/11 9/16/11 10/7/11 12/1/11 12/26/11 2/11/12 4/17/12 5/13/12 6/8/12 7/16/12 9/27/12 10/14/12 11/17/12 1/25/13 2/23/13 3/21/13 4/15/13 5/21/13 6/9/13 8/21/13 9/26/13 11/21/13 11/30/13 12/30/13 2/4/14 3/26/14 4/19/14 5/10/14 ADMIT DATE
32 The standard approach: why? Medications NICU Finnegan Scores
33
34 The infant with a score of 7 or less was not treated with drugs for the abstinence syndrome because, in our experience, he would recover rapidly with swaddling and demand feedings. Infants whose score was 8 or above were treated pharmacologically Finnegan LP, et al. Assessment and treatment of abstinence in the infant of the drug- dependent mother. Int Clin Pharmacol Biopharm. 1975;12(1 2):19 32
35 Problems with the Finnegan Long lengths of stay and lots of meds Purpose of treatment is to get the scores below threshold Must disturb the infant and exacerbate signs of withdrawal Can be slow to respond Powerful and potentially harmful meds to give to treat a sneeze or a yawn
36 Intervention 3 Discontinuation of the Finnegan Scoring tool and adoption of a functional scoring approach 36
37 1)Can the baby eat? 2)Can the baby sleep? 3)Can the baby be consoled?
38 ESC Study Analyzed 50 consecutive NAS babies admitted to our general inpatient unit from March 2014 to August 2015 Assessed every 2-6 hours using the FNASS, but did not guide management Management decisions based on ESC
39 Outcomes 1. Proportion of infants treated with morphine vs. proportion predicted to be treated with morphine using the FNASS approach 2. Days the two approaches disagreed 3. FNASS scores the day after the two approaches disagreed
40 Results Proportion of Infants that Received Morphine 80% 70% 60% 50% p< % 40% NAS infants (n=50) 30% 20% 10% 12% 0% Received Morphine (ESC) Would Have Received Morphine (Finnegan)
41 Results by Hospital Day Hospital Days (n=296): ESC Approach FNASS Approach Predicted P value Increased Morphine 8 (2.7%) 76 (26%) <0.01 No Morphine 258 (87.2) 156 (52.7%) <0.01 Decreased Morphine 21 (7.1%) 35 (11.8%) <0.01 Same Morphine 9 (3%) 29 (9.8) <0.01
42 Results On 78 days (26.4%) the ESC Led to LESS Morphine than Predicted by The Finnegan The following day, the average Finnegan score decreased by 0.9 points, and decreased in 69% of cases. On 2 days (0.7%) the ESC Led to MORE Morphine than Predicted by The Finnegan In both cases the average Finnegan score increased by 1.7 Points the next day
43 Results No readmissions No seizures No ICU transfers
44 Withdrawal from opioids or sedative-hypnotic drugs may be life-threatening, but ultimately, drug withdrawal is a selflimited process. Unnecessary pharmacologic treatment will prolong drug exposure and the duration of hospitalization to the possible detriment of maternalinfant bonding. The only clear benefit of pharmacologic treatment is the short-term amelioration of clinical signs. Hudak ML, Tan RC; COMMITTEE ON DRUGS; COMMITTEE ON FETUS AND NEWBORN; American Academy of Pediatrics: Neonatal drug withdrawal. Pediatrics 2012; 129:e540 e560
45 Source:
46 The standard approach: why? Medications NICU Finnegan Scores Medication Dosing
47
48 Intervention 5 Decrease in morphine up to 3 times per day 48
49 Intervention 6 PRN Dosing
50 Length of Stay: Methadone exposed infants 70.0 Standardized non-pharm care Novel assessment tool on inpatient unit 60.0 Direct transfer to inpatient unit Spread to NICU team Prenatal counseling 50.0 UCL Mean=22.5 Rapid med weaning LENGTH OF STAY (Days) Mean=13.2 Mean=10.2 Mean= LCL 0.0 1/30/08 7/2/08 8/30/08 11/19/08 1/13/09 2/19/09 5/5/09 6/13/09 9/10/09 10/21/09 2/2/10 3/12/10 6/23/10 10/10/10 12/10/10 2/9/11 3/8/11 5/10/11 6/10/11 9/10/11 10/7/11 12/1/11 1/5/12 4/3/12 5/13/12 6/26/12 8/20/12 10/12/12 11/17/12 1/25/13 3/6/13 4/4/13 5/21/13 7/4/13 9/10/13 11/20/13 11/30/13 1/12/14 2/19/14 4/12/14 5/10/14 6/14/14 6/26/14 8/7/14 9/23/14 11/19/14 1/6/15 2/16/15 4/14/15 ADMIT DATE
51 The standard approach: why? Medications NICU Finnegan Scores Medication Dosing Staff cares for the baby
52 Cleveland, et al., JOGNN;43(3):
53 How do moms feel? Addiction is misunderstood Guilty Judged Mistrusting of nurses
54 I would just tell (the nurses) to take it easy (on the mother). You know, after being addicted, I realized that this is really a disease. There are some who abuse, but if you re using while you re pregnant, you have a problem; a big problem and you need help
55 His nurse was like his muscles are locking up because of his junkie mom. I didn t want to visit, I would call before and if that nurse was there, I wouldn t even go.
56 because we re gonna leave and he s gonna cry and they re gonna leave him crying because they re gonna be like, you know what? His parents are jerks!
57 Intervention 7 Empowering messaging
58 Source:
59 Source:
60 Old Protocol Goal: suppress withdrawal signs NICU: Mom visits Finnegan Scores: treat the number supportive care feed on demand Morphine Surprise! Staff takes care of infant New Protocol Goal: have infant function as a normal neonate Mother and child together Eat/Sleep/Console: treat the infant SUPPORTIVE CARE No feeding schedule Meds on page 3 Prenatal preparation Staff coaches parents
61 Length of Stay: Methadone exposed infants 70.0 Standardized non-pharm care 60.0 Direct transfer to inpatient unit 50.0 UCL Mean=22.5 Novel assessment tool on inpatient unit Prenatal counseling LENGTH OF STAY (Days) Mean=13.2 Mean=10.2 Spread to NICU team Rapid med weaning Mean=7.7 Meds as needed Empowering messaging Mean= LCL 1/30/08 7/12/08 11/10/08 1/21/09 4/6/09 6/13/09 9/18/09 12/23/09 3/19/10 9/18/10 12/10/10 2/21/11 4/27/11 7/4/11 9/29/11 12/1/11 2/11/12 5/7/12 6/26/12 10/9/12 11/17/12 2/23/13 3/28/13 5/22/13 8/21/13 11/20/13 12/10/13 2/11/14 4/19/14 6/8/14 6/26/14 9/8/14 11/14/14 1/9/15 3/11/15 5/26/15 7/17/15 8/22/15 10/21/15 12/4/15 4/28/16 7/7/16 8/31/16 9/27/16 10/29/16 12/21/16 1/19/17 3/3/17 4/3/17 4/30/17 5/28/17 6/25/17 ADMIT DATE 0.9
62 Average Length of Stay - Methadone Exposed Infants Average Length of Stay (Days) Protocol Change: More aggressive weans Focus on supportive management Transfers directly from WBN to Floor Discontinued Finnegan Scoring NICU included in effort Length of Stay (days) Year More aggressive weans
63 Percent of NAS Patients Treated with Morphine 100.0% 90.0% 80.0% % Treated with Morphine 70.0% 60.0% 50.0% 40.0% 30.0% % Treated with Morphine 20.0% 10.0% 0.0% Year
64 Percent Treated with Morphine 100.0% 90.0% 80.0% 70.0% Percent Treated 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Date
65 Percent of NAS Patients Treated with Morphine 100.0% 90.0% 80.0% % Treated with morphine 70.0% 60.0% 50.0% 40.0% 30.0% NICU non-nicu 20.0% 10.0% 0.0% Year
66 Average Length of Stay - Methadone Exposed Infants Average Length of Stay Average Length of Stay Year
67 Average Length of Stay - Methadone Exposed Infants Average Length of Stay NICU non-nicu Year
68 Average Maximum Morphine Dose 0.6 Average maximum morphine dose (mg/dose) p <.001 Average maximum morphine dose (mg/dose) Year
69 60.0% Breastfeeding Rate 50.0% 40.0% % Breastfeeding 30.0% 20.0% % Breastfeeding 10.0% 0.0% Year
70 Total Average Cost of NAS Care p <.001 Total Cost ($) Total Cost ($) Year
71 BMC QI Initiative Cycle 1: May 2016 Staff education Prenatal messaging Non-pharm care bundle Finnegan symptom prioritization Cycle 2: July 2016 Methadone No Tx in the first 24 hours Cycle 3: Dec 2016 Eat, Sleep, Console (ESC) Cuddlers
72 Symptom Prioritization Central Nervous System Disturbances Excessive High Pitched Crying 2 Continuous High Pitched Crying - 3 Sleep < 1 Hr After Feeding 3 Sleep < 2 Hr After Feeding 2 Sleep < 3 Hr After Feeding 1 Hyperactive Moro Reflex 2 Markedly Hyperactive Moro 3 Mild Tremors Disturbed 1 Mod Sev Tremors Disturbed 2 Mild Tremors Undisturbed 3 Mod Sev Tremors Undisturbed - 4 Metabolic, Vasomotor, and Respiratory Disturbance Gastrointestinal Disturbance Sweating 1 Excessive Sucking 1 Fever < 101 ( C) 1 Fever > 101 (38.4 C) 2 Poor feeding 2 Frequent Yawning (>3) 1 Regurgitation 2 Projective Vomiting 3 Mottling 1 Loose Stools 2 Watery Stools 3 Nasal Stuffiness 1 Increased Muscle Tone - 2 Sneezing (>3) 1 Excoriation 1 Nasal Flaring 2 Myoclonic Jerk 3 Respiratory Rate (>60) 1 Respiratory Rate (>60 Retractions) 2 Seizures 5
73 ESC EPIC flowsheet
74 ESC EPIC Flowsheet
75 Percent of infants pharmacologically treated _ _ % Treated Average UCL and LCL Percent 100% UCL Non-Pharm Care Bundle Symptom prioritization Prenatal education 90% 80% Percent treated 70% 60% 50% 40% 30% LCL ESC Care Tool Cuddlers 20% 10% Mean 86% Staff QI education 0% 1/1/14 2/1/14 3/1/14 4/1/14 5/1/14 6/1/14 7/1/14 8/1/14 9/1/14 10/1/14 11/1/14 12/1/14 1/1/15 2/1/15 3/1/15 4/1/15 5/1/15 6/1/15 7/1/15 8/1/15 9/1/15 10/1/15 11/1/15 12/1/15 1/1/16 2/1/16 3/1/16 4/1/16 5/1/16 6/16/16 7/16/16 8/1/16 9/1/16 10/1/16 11/1/16 12/1/16 1/1/17 2/1/17 3/1/17 Mean 44% Month of admission
76 Pharmacologically treated infants who received adjunctive medication _ _ % Adjunctive Medications Average UCL Percent Percent with adjunctive medication 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 1/1/14 UCL LCL 2/1/14 3/1/14 4/1/14 5/1/14 6/1/14 7/1/14 8/1/14 9/1/14 10/1/14 Mean 34% 11/1/14 12/1/14 1/1/15 2/1/15 3/1/15 4/1/15 5/1/15 6/1/15 7/1/15 8/1/15 9/1/15 10/1/15 11/1/15 12/1/15 Month of admission Non-Pharm Care Bundle Symptom prioritization Prenatal education Staff QI education 1/1/16 2/1/16 3/1/16 4/1/16 5/1/16 Methadone 6/16/16 7/16/16 8/1/16 9/1/16 ESC Care Tool Cuddlers 10/1/16 11/1/16 12/1/16 Mean 0% 1/1/17 2/1/17 3/1/17
77 Length of hospital stay for all opioid-exposed infants Measure Hospital days UCL Mean 18.4 days Non-Pharm Care Bundle Symptom prioritization Prenatal education _ _ LOS Average UCL and LCL Staff QI Education Methadone ESC Care Tool Cuddler s Mean 10.4 days 10 0 LCL Jan 2014 Feb 2014 March 2014 April 2014 May 2014 June 2014 July 2014 Aug 2014 Sept 2014 Oct 2014 Nov 2014 Dec 2014 Jan 2015 Feb 2015 March 2015 April 2015 May 2015 June 2015 July 2015 Aug 2015 Sept 2015 Oct 2015 Nov 2015 Dec 2015 Jan 2016 Feb 2016 March 2016 April 2016 May 2016 June 2016 July 2016 Aug 2016 Sept 2016 Oct 2016 Nov 2016 Dec 2016 Jan 2017 Feb 2017 March 2017 Month of admission
78 LCL 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00% 90.00% % Measure Mean 80% Percent Parental Presence Mean 50%
79 New ESC Tool
80 Additional Spread
81 Long-Term Outcomes?
82 Conclusions Hugs before drugs Empower families Rooming-in Non-Pharmacologic care as 1 st line treatment ESC approach PRN meds Ask why Source: Grossman Family Album
83 Acknowledgements David Hersh, MD Adam Berkwitt, MD Erin Nozetz, MD Marcelle Applewaite, RN Kim Carter, RN Liz O Mara Matt Bizzarro, MD Yogangi Malhotra, MD Jonathan Miller, MD Camisha Taylor, RN Rachel Osborn, MD
Neonatal Abstinence Syndrome:
Neonatal Abstinence Syndrome: Reconsidering the Standard Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital
More informationEAT, SLEEP, CONSOLE The Yale Method of assessment and treatment of neonates during withdrawal from opiates
EAT, SLEEP, CONSOLE The Yale Method of assessment and treatment of neonates during withdrawal from opiates NICOLE DUNCAN BSN, RN, CPN MAY 2018 Pediatric Educator, MultiCare Health System DISCLAIMER I have
More informationOpioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome
Opioid Use Disorder in Pregnancy Neonatal Abstinence Syndrome Opioid Use Disorder and Pregnancy Cont. 4.6 million women (or 3.8 percent) ages 18 and older misused prescription drugs in 2013. One-third
More informationNeonatal Abstinence Syndrome
5 Neonatal Abstinence Syndrome Amy P. Holmes, PharmD Introduction Neonatal abstinence syndrome (NAS) is recognized as the effect of intrauterine exposure to substances that can cause physical dependence.
More informationLori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center
Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center NSDUH, 2012 National Survey on Drug Use and Health: 2012 Substance abuse: Public Health Problem
More informationCare of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine
More informationNeonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention
Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention Cynthia Thomas, DO,MPH Northeast Regional Health Office Tennessee Department of Health Disclosure Statement of Financial
More informationWales Neonatal Network Guideline
Guideline on the Management of Neonatal Abstinence Syndrome Introduction Neonatal Abstinence Syndrome (NAS) is a constellation of symptoms and signs occurring in a baby as a result of withdrawal from physically
More informationObjectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationIN-PATIENT PEDIATRIC REHABILITATION
IN-PATIENT PEDIATRIC REHABILITATION Neonatal Abstinence Syndrome Program Carissa H. Snelling, MS, OTR/L, BCP Erika Herzer, PT, DPT, PCS, CBIS April 2017 CHARACTERISTICS OF NAS Drug(s) Opioids Cocaine Benzodiazepines
More informationNeonatal Drug Withdrawal
History Neonatal Drug Withdrawal Katherine Wang, MD, FAAP Avera McKennan Children s Hospital NICU Morphine has been used for pain for many years Congenital morphinism was not recognized as an entity until
More informationClinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP
Clinical Management of Neonatal Abstinence Syndrome Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Timeline Incidence of NAS Healthcare Cost and Utilization Project (HCUP), 1999-2013 State Inpatient Databases
More informationObjectives. Common Drugs leading to NAS. Differential Diagnosis. Clinical Features of NAS. Assessing Neonatal Abstinence in the Newborn Nursery
Objectives Assessing Neonatal Abstinence in the Newborn Nursery WAPC Annual Meeting 2012 Elizabeth Goetz MD Mary Rolloff PhD, RN, CNE At the conclusion of this session participants will be able to: Understand
More informationThe Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome
Neonatal Nursing Education Brief: The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome https://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/
More informationDevelopment and use of the Eating, Sleeping, Consoling (ESC) Care. for opioid-exposed newborns and their families in Northern New England
Development and use of the Eating, Sleeping, Consoling (ESC) Care Tool to promote healthy beginnings for opioid-exposed newborns and their families in Northern New England Bonny Whalen, MD Oct 5, 2018
More informationPresented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay
Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay Overview/Learning Objectives What is Addiction Medication Assisted Treatment Discuss facts about
More informationNeonatal Abstinence Syndrome (NAS)
Neonatal Abstinence Syndrome (NAS) Dhara D. Shah, PharmD PGY-1 Pharmacy Practice Resident January 31, 2018 Program for HealthTrust Members Disclosures This program may contain the mention of drugs or brands
More informationSupersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required
Effective Date 12/13/16 Neonatal Abstinence Syndrome (NAS) Date Approved 12/13/16 Guideline Pharmacologic Protocol Supersedes Date None and Management Guidelines Originating Dept. NICU Document Owner Dir.,
More informationRunning head: NEONATAL ABSTINENCE SYNDROME 1
Running head: NEONATAL ABSTINENCE SYNDROME 1 Nursing Treatment of Neonatal Abstinence Syndrome Ferris State University Kelly Geraghty, Tracy James, Kristen Lintjer, Sara Potes, Rikki Zissler NEONATAL ABSTINENCE
More informationProduct Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD
1 The National Academies of Sciences, Engineering and Medicine Regulatory Strategies of address prescription opioidrelated harms 4 th of November, 2016 Washington DC Product Labeling to Communicate Benefits
More informationDonor human milk may decrease severe gastrointestinal distress in infants with neonatal abstinence syndrome.
Research Article http://www.alliedacademies.org/pregnancy-and-neonatal-medicine/ Donor human milk may decrease severe gastrointestinal distress in infants with neonatal abstinence syndrome. Catherine Alexander,
More informationNeonatal abstinence syndrome
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Neonatal Abstinence Syndrome. These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More information9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment
Postpartum Counseling for Women in MAT Katie Clark MSPH, CSAC A little about Katie SUD and PH crossroads BA Health Arts and Sciences Goddard College MSPH MCH UNC Project Lazarus, Yale, CHER Solutions LLC
More informationOpioid use in pregnancy and Neonatal Abstinence Syndrome
Opioid use in pregnancy and Neonatal Abstinence Syndrome Morissa Ladinsky, MD Assoc. Professor of Pediatrics Division of General Pediatrics and Adolescent Medicine UAB Objectives 1. Understand the magnitude,
More informationNAS / NOWS: Description. Disclosures: I will discuss off-label uses of medications I have no financial disclosures. Objectives
Opioid-exposed Newborns and Their Families the Vermont Approach Anne Johnston, MD Neonatal Perinatal Medicine Associate Professor of Pediatrics University of Vermont Disclosures: I will discuss off-label
More informationOpioids in Pregnancy. Beyond to Baby GENERAL INFO
Opioids in Pregnancy and Beyond to Baby by Marcia W. VanVleet, MD, MPH Medical Director, Newborn Service Team, Women and Infants Hospital, and Assistant Professor of Pediatrics, Brown Alpert Medical School,
More informationNeonatal Abstinence: It s No Child s Play!
Neonatal Abstinence: It s No Child s Play! Claudia Summa BScPhm Pharmacy Resident Wednesday, March 28, 2007 Objectives To present a case of neonatal abstinence syndrome (NAS) To discuss the incidence,
More informationA New approach to NAS: home in 6 days
+ A New approach to NAS: home in 6 days Lisa Grisham, NNP-BC Moe Kane, NNP-BC Banner University Medical Center - Tucson University of Arizona, College of Medicine Department of Pediatrics Division of Neonatology
More informationEmergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC
Emergent Issues Affecting Early Intervention/ Early Childhood Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC Conversation Points Changing Demographics Emergent Trends
More informationNeonatal Abstinence: The epidemic Its Impact on All of Us
Neonatal Abstinence: The epidemic Its Impact on All of Us Michelle Bode MD, MPH Neonatologist Crouse Hospital Assistant Professor Pediatrics SUNY Upstate Objectives & Disclosure Statement 1) The participant
More information4/19/2017. Neonatal Abstinence Syndrome. Disclosures. Objectives. Kara Kuhn-Riordon, MD UC Davis Medical Center. I have no financial disclosures
Neonatal Abstinence Syndrome Kara Kuhn-Riordon, MD UC Davis Medical Center Disclosures I have no financial disclosures Objectives Identify the substances associated with neonatal abstinence syndrome (NAS)
More informationI llicit drug use during pregnancy is a major medical and
ORIGINAL ARTICLE Measurement of movement is an objective method to assist in assessment of opiate withdrawal in newborns C O Brien, R Hunt, H E Jeffery... See end of article for authors affiliations...
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome Jodi Jackson, MD* Betsy Knappen, MSN, APRN** *Chair Kansas Perinatal Quality Collaborative (KPQC) Medical Director NICU, Shawnee Mission Medical Center (SMMC) Neonatologist,
More informationObjectives. Nothing to Disclose No Conflicts of Interest
April 22, 2014 PCSS-MAT Webinar Lori Devlin, DO, MHA Assistant Professor- Department of Pediatrics University of Louisville School of Medicine Nothing to Disclose No Conflicts of Interest Objectives Define
More informationPROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3
PROJECT DOVE Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3 Partners Support Bureau of Justice Assistance, Department of Justice Grant # PM-BX-Koo4 Treatment Plan MODULE
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationSUBSTANCE EXPOSED INFANTS PRESENTED BY ECOLE J. BARROW-BROOKS M.ED & DARLENE D. OWENS MBA, LBSW, CADC, ADS
SUBSTANCE EXPOSED INFANTS PRESENTED BY ECOLE J. BARROW-BROOKS M.ED & DARLENE D. OWENS MBA, LBSW, CADC, ADS 1 SUBSTANCE-EXPOSED INFANTS Refers to infants exposed to alcohol and or other substances ingested
More informationAdvancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance
Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical
More informationADDICTION IN PREGNANCY
ADDICTION IN PREGNANCY R. Corey Waller MD, MS, DFASAM Sr. Medical Director, Education and Policy The National Center for Complex Health and Social Needs DISCLOSURES No relevant disclosures OBJECTIVES The
More information8/27/2018. Katie Brooks, DO, FAAP CHI Health St. Elizabeth. I have nothing to disclose
Katie Brooks, DO, FAAP CHI Health St. Elizabeth I have nothing to disclose 1 Briefly review the history of NAS and current prevalence Understand definition of NAS and which motherbaby dyads should be screened
More informationOMT FOR THE NAS INFANT. Eren Ural OGME II
OMT FOR THE NAS INFANT Eren Ural OGME II Objectives: 1. Review the signs and symptoms monitored for diagnosing Neonatal Abstinence Syndrome 2. Understand current medical management for Neonatal Abstinence
More informationNeonatal Abstinence Syndrome (NAS)
Neonatal Abstinence Syndrome (NAS) Jodi Jackson, MD Neonatologist Children's Mercy Hospital Associate Professor of Pediatrics University of Missouri-Kansas City School of Medicine Medical director NICU
More informationNeonatal Intensive Care Unit Clinical Guideline. Abstinence and Withdrawal in Neonates. Background
Neonatal Intensive Care Unit Clinical Guideline Abstinence and Withdrawal in Neonates Background (NAS) is a combination of behavioural and physiological signs and symptoms that occur in newborn babies
More informationRelationships Relationships
PRENATAL OPIATE EXPOSURE IMPACT ON EARLY CHILDHOOD LEARNING AND BEHAVIOR Ira J. Chasnoff, MD NTI Upstream www.ntiupstream.com Children grow and develop in the context of Attachment: Basic Concept Attachment:
More informationConsequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018
Consequences and Treatment of Opioid Abuse During Pregnancy Katie Ellis, PharmD March 12, 2018 Disclosure I have nothing to disclose. Objectives At the completion of this activity, the pharmacist will
More informationOhio Perinatal Quality Collaborative
Ohio Perinatal Quality Collaborative Neonatal Abstinence Syndrome Project Presented by Michele Walsh MD Neonatal Lead Physician December 2017 Disclosure I have no financial or other conflicts of interest.
More informationNEONATAL ABSTINENCE SYNDROME
NEONATAL ABSTINENCE SYNDROME P Kocherlakota MD Division of Neonatology Department of Pediatrics Maria Fareri children's Hospital at West Chester Medical Center New York Medical College, Valhalla, NY DISCLOSURES
More informationClinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13
Clinical Policy: Reference Number: CP.MP.86 Effective Date: 10/13 Last Review Date: 10/17 See Important Reminder at the end of this policy for important regulatory and legal information. Revision Log Description
More informationNeonatal Abstinence Syndrome: An Evidence- Based Review for the Family Nurse Practitioner
Southern Adventist Univeristy KnowledgeExchange@Southern Graduate Research Projects Nursing 8-2014 Neonatal Abstinence Syndrome: An - Based Review for the Family Nurse Practitioner Kindra Romer Follow
More information10/15/2018. The Tiniest Victims of the Opioid Crisis Tara Sundem, RN, NNP-BC, MS
The Tiniest Victims of the Opioid Crisis Tara Sundem, RN, NNP-BC, MS What is Neonatal Abstinence Syndrome (NAS)? What causes NAS? Signs and Symptoms of NAS? Treatment of NAS? Follow up for babies with
More informationNOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome
NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome Meghan Howell, MD FAAP Assistant Professor of Pediatrics Clinical Director, Tulane NICU Graduate Clinic Tulane University School
More informationMaternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015
Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples
More informationNEONATAL ABSTINENCE SYNDROME. Michael Donnelly, D.O., PGY-2 Lake Cumberland Regional Hospital Somerset, KY
NEONATAL ABSTINENCE SYNDROME Michael Donnelly, D.O., PGY-2 Lake Cumberland Regional Hospital Somerset, KY Disclosures I have no financial disclosures to discuss Objectives Discuss the history of Neonatal
More informationA System of Care Surrounding the Drug Exposed Neonate. Disclosures. Objectives 11/17/2015. I have no financial disclosures
A System of Care Surrounding the Drug Exposed Neonate Sean Loudin MD Disclosures I have no financial disclosures Objectives Discuss the epidemiology of Neonatal Abstinence Syndrome (NAS) both nationally
More informationNeonatal Abstinence Syndrome: A Retrospective Review of Clonidine as an Adjunct to Opioid Treatment
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 9-28-2010 Neonatal Abstinence Syndrome: A Retrospective Review of
More informationNon-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS) Michael
More informationILPQC Mothers and Newborns Affected by Opioids (MNO) Workgroup. November 20 th, :00 2:00 pm
ILPQC Mothers and Newborns Affected by Opioids (MNO) Workgroup November 20 th, 2017 1:00 2:00 pm Overview Updates (5 min) MNO Survey (5 min) MNO AIM Statement (10 min) Literature Reviews NAS Pharmacotherapy
More informationNeurodevelopmental Risk?
Normal Newborn During transitional hypoglycemia normal newborns have an enhanced ketogenic response to fasting. Newborn brains have enhanced capability to use ketone bodies for fuel Allows newborns to
More information... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot
Department of... Health Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN Overview and Regional Snapshot Cynthia C. Thomas, DO, MPH, Assistant Health Officer, Northeast Regional Health
More information8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY
ADDICTION AND PREGNANCY L y n é e B r o w n, M A, C D P & D o n n a L i v i n g s t o n, R N A D A P T E D F R O M J i m W a l s h, M D Objectives: Recognize common fears and myths associated with substance
More informationOutcomes of Infants with Neonatal Abstinence Syndrome
Outcomes of Infants with Neonatal Abstinence Syndrome Caroline O. Chua, MD, FAAP Medical Director, Division of Neonatology Director, Neonatal Follow Up Clinic Nemours Children s Hospital Orlando, Florida
More informationOpioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard
Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among
More informationBorn on Opioids 11/15/2018. Current Epidemic of Opiates. Opioid Exposed Infant. Khalid Awad, MD
Born on Opioids Khalid Awad, MD Methodist Women s Hospital Neonatology Opioid Exposed Infant Screening to identify at risk infants Objective scoring FNASS/ESC Interventions: non-pharmacologic & pharmacologic
More informationScience = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse
Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome Linda Wallen, M.D. Clinical Professor of Pediatrics Univ of Washington/ Seattle Children s Hospital Many slides courtesy of Christine Gleason, MD I do not have any conflict
More informationTreating Women for Opioid Use Disorder during Pregnancy: Methadone and Buprenorphine as a Part of a Complete Care Approach
Treating Women for Opioid Use Disorder during Pregnancy: Methadone and Buprenorphine as a Part of a Complete Care Approach Hendrée E. Jones, PhD Executive Director, UNC Horizons Professor, Department of
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More informationJohann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works
From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome TAMARA HARVANKO RN, BAN HIGH RISK OB CARE COORDINATOR CASE MANAGEMENT HENNEPIN COUNTY MEDICAL CENTER TAMARA.HARVANKO@HCMED.ORG 612-873-6552 https://www.youtube.com/watch?v=tk2hoyupkvi
More informationSERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY
SERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY A Snapshot of the Data, Services, and Outcomes Jerome M. Reyerson, LCSW-C Director, Harford County Department of Social Services GLIMPSE OF A SUBSTANCE
More informationNeonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives
Neonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives Brevard County Health Department Melbourne, FL April 7, 2017 Mark L. Hudak, MD Professor and Chairman of Pediatrics University
More informationMethadone and Pregnancy
Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine
More informationTHE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE
THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE THE 6 TH ANNUAL IVEY SYMPOSIUM Ron Abrahams, Claudette Chase, Judy Desmoulin, Mel Kahan, David Knoppert, Gideon Koren, Laura Lyons, Alice Ordean, Henry
More informationNEONATAL CLINICAL PRACTICE GUIDELINE
NEONATAL CLINICAL PRACTICE GUIDELINE Title: Neonatal Substance Exposure: Assessment and Clinical Management Approval Date: February 2018 Approved by: Neonatal Patient Care Teams, HSC & SBH Child Health
More informationNEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE
NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE Salma Ali MD, Debra Brendel RN, BSN, MSN and Ona Fofah MD Division of Neonatology and Newborn Medicine Department of
More informationNursing Care of the NAS Infant. Lori Markham MSN, MBA, ARNP, NNP-BC
Nursing Care of the NAS Infant Lori Markham MSN, MBA, ARNP, NNP-BC Objectives Define neonatal abstinence syndrome Recognize the clinical presentation Identify non-pharmacologic and pharmacologic caregiver
More informationPain Control in the NICU
Pain Control in the NICU By Robert Cicco, MD Introduction There is ample documentation in the literature that newborn infants experience pain and exhibit a variety of both physiologic and behavioral responses
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationImpact of Parental Presence at Infants Bedside on Neonatal Abstinence Syndrome
RESEARCH ARTICLE Impact of Parental Presence at Infants Bedside on Neonatal Abstinence Syndrome Mary Beth Howard, MD, MSc, a Davida M. Schiff, MD, b Nicole Penwill, BA, c Wendy Si, MD, c Anjali Rai, MD,
More informationNeonatal Abstinence Syndrome In Kentucky. Annual Report. From the Public Health Neonatal Abstinence Syndrome Reporting Registry
Kentucky Department for Public Health Division of Maternal and Child Health Data Brief December 2015 Neonatal Abstinence Syndrome In Kentucky Annual Report From the Public Health Neonatal Abstinence Syndrome
More information2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society
Pregnant Women Who Use Drugs: Stigma, Science and Society Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia
More informationThe Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital
Volume 3 Issue 3 Article 10 2017 The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital Sydni Fazenbaker Crowell, Allison M. Crump-Rogers, William Crump, and LeAnn Langston
More informationInequalities in health and their effect on the newborn
Inequalities in health and their effect on the newborn Dr Kathryn Johnson Leeds Neonatal Service Leeds Teaching Hospitals NHS Trust Consultant Neonatologist Research lead Neonatal Abstinence Syndrome Covered
More informationDisclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond
Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More informationMOMS Project Panel Overview
MOMS Project Panel Overview Rick Massatti, PhD, Ohio Department of Mental Health and Addiction Services Jennifer Bailit, MD, MetroHealth Medical Center Mike Marcotte, MD, Tri-Health Mona Prasad, DO,MPH,
More informationMEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution IMPORTANT: Keep morphine sulfate oral solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationSTARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening
More informationSummary of Changes: References/content updated to reflect most current standards of practice.
Alaska Native Medical Center: Mother Baby Unit Guideline: Neonatal Hypoglycemia Subject: Neonatal Hypoglycemia REVISION DATE: Jan 2015,12/2011, 02/2009, 11, 2007, 07/2007,04/2001, 04/1999 REPLACES: NSY:
More informationDilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such as that due to:
DrugFAQs Dilaudid Generic name: Hydromorphone hydrochloride Brand names: Dilaudid Why is Dilaudid prescribed? Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such
More informationMEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only
MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationOverdose Prevention and Intervention Task Force January 10, 2018
Overdose Prevention and Intervention Task Force January 10, 2018 CO-CHAIRS: DIRECTOR NICOLE ALEXANDER-SCOTT, MD, MPH, RHODE ISLAND DEPARTMENT OF HEALTH DIRECTOR REBECCA BOSS, MA, RHODE ISLAND DEPARTMENT
More informationThe Impact of the Opioid Crisis on Children
The Impact of the Opioid Crisis on Children Guided Notes for Online Learning Name: Date: 1 Table of Contents Section 1: The Opioid Crisis Page 3 Section 2: Addiction Page 4 Section 3: Trauma Informed Care
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationLearning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons
Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Marianna Corona Jennifer Foley September 12, 2017 Learning Objectives 2017 Improving Family Outcomes
More information1/26/2018 PREVENTING THE RETRAUMITIZATION OF CHILDREN FROM ADDICTED FAMILIES THE PROBLEM RISK FACTORS FOR ENDANGERMENT
PREVENTING THE RETRAUMITIZATION OF CHILDREN FROM ADDICTED FAMILIES Susan Kilman LCSW, AADC THE PROBLEM ABOUT 1 IN 8 (8.7 MILLION) AGED 17 OR YOUNGER LIVE IN HOUSEHOLDS WITH AT LEAST ONE PARENT WHO HAD
More informationNeonatal Abstinence Syndrome Management From Prenatal Counseling to Postdischarge Follow-up Care: Results of a National Survey
RESEARCH ARTICLE Neonatal Abstinence Syndrome Management From Prenatal Counseling to Postdischarge Follow-up Care: Results of a National Survey AUTHORS Aakriti Mehta, BA, 1 Kathryn Dawn Forbes, MD, MS,
More informationBeyond Birth: A Comprehensive Recovery Center serving parenting women
Beyond Birth: A Comprehensive Recovery Center serving parenting women Session Objectives Highlight Plan of Safe Care Introduce the Beyond Birth Comprehensive Recovery Center Describe Levels of Care The
More information